LoL...it has been a while
I first established a position in early 2014.....yes, they've advanced Apabetalone, their lead and really only compound to Phase 3. Its an events based trial that has reached it's required 250 Events, with top-line results expected in about 2 months time....Late June or into July.
Its Epigenetics and they have the only Phase 3 compound in late stage development....they've disclosed having other compounds in their pipeline, but the compnay is pretty much broke. My best guess is they have about $7 million USD left in the bank....just enough to get them to Top-Line results....and then if the results are good, I expect they'll be doing a raise at that time, possibly in tandem with garnering a listing in the US.
Major owner at about 40% is Chinese Pharma Shenzhen Hepalink, reportedly the world's largest supplier of blood thinner Heparin Sodium.
Any questions fire away....but not too heavy duty on the science. I don't write peer reviewed articles for scientific journals :)
If you want to taste the fruit, you have to go out on a limb. But if you wait for the herd to move out on the limb....the branch tends to snap.
